Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.

Nature medicine - 1 Oct 2005

Waza Masahiro, Adachi Hiroaki, Katsuno Masahisa, Minamiyama Makoto, Sang Chen, Tanaka Fumiaki, Inukai Akira, Doyu Manabu, Sobue Gen

Abstract excerpt

Heat-shock protein 90 (Hsp90) functions as part of a multichaperone complex that folds, activates and assembles its client proteins. Androgen receptor (AR), a pathogenic gene product in spinal and bulbar muscular atrophy (SBMA), is one of the Hsp90 client proteins. We examined the therapeutic effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG), a potent Hsp90 inhibitor, and its ability to degrade...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Trinucleotide Repeat Expansion
Share to Benzoquinones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Lactams, Macrocyclic

Share to Motor Neurons

Share to Muscular Atrophy, Spinal

Share to Peptides

Share to Receptors, Androgen

Source

Identifiers

PMID: 16155577
DOI: 10.1038/nm1298

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.PMID 16155577Read ↗

Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).Semantic proximity Read ↗

Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.Semantic proximity Read ↗

17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy.Semantic proximity Read ↗

Therapeutic approaches to spinal and bulbar muscular atrophy.Semantic proximity Read ↗

Hsp90 as a therapeutic target in prostate cancer.Semantic proximity Read ↗

Hsp90 inhibition protects against inherited retinal degeneration.Semantic proximity Read ↗

Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's DiseasesSemantic proximity Read ↗

ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor.Semantic proximity Read ↗

[Development of therapeutics for spinal and bulbar muscular atrophy (SBMA)].Semantic proximity Read ↗

Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein.Semantic proximity Read ↗

Enhanced aggregation of androgen receptor in induced pluripotent stem cell-derived neurons from spinal and bulbar muscular atrophy.Semantic proximity Read ↗

Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.